RCZY-698 / Rongchang Pharma - LARVOL DELTA

RCZY-698: An orally bioavailable, highly potent, and selective reversible KRASG12V (ON)-state inhibitor with robust antitumor activity in preclinical models of KRASG12V-driven solid tumors (AACR 2026) - "In a panel of KRASG12V-mutant tumor cell lines, RCZY-698 elicits potent antiproliferative effects, demonstrating superior in vitro growth inhibition compared with RMC-5127. Collectively, these data delineate the discovery and preclinical profiling of RCZY-698 as a novel oral non-covalent KRASG12V(ON)-selective tri-complex inhibitor with compelling in vitro potency and in vivo efficacy. Further efforts and characterization work are being implemented to complete the preclinical candidate (PCC) data package for RCZY-698."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • KRAS